Anaplastic large-cell lymphoma (ALCL) is a non-Hodgkin T-cell lymphoma characterized by persistent expression of CD 30 antigen that represents 2–3% of non-Hodgkin lymphoma (NHL). ALCL may present as a primary cutaneous disease or systemic disease with secondary cutaneous involvement. World Health Organization (WHO) classifies ALCL into ALK-positive and ALK-negative ALCL. ALK-negative ALCL shows poor response on treatment and has a bad prognosis. We report locally aggressive and metastasizing primary cutaneous anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma in a 58-year-old female, due to its paucity of literature.
No takes yet. Share an insight, caveat, or question.
Kote et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: